We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+0.42%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
+$499M
Cap. Flow
+$505M
Cap. Flow %
26.59%
Top 10 Hldgs %
45.18%
Holding
85
New
22
Increased
26
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$130M
2
FOLD
Amicus Therapeutics
FOLD
+$49.2M
3
ALC icon
Alcon
ALC
+$47.1M
4
RVMD icon
Revolution Medicines
RVMD
+$46.1M
5
EXAS
Exact Sciences
EXAS
+$35.6M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$82M
2
URGN icon
UroGen Pharma
URGN
+$23.8M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$18.1M
4
LQDA icon
Liquidia Corp
LQDA
+$18.1M
5
ESTA icon
Establishment Labs
ESTA
+$17.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
76
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
– –
-200,000
Closed -$5.02M
IMVT icon
77
Immunovant
IMVT
$8.2B
– –
-350,000
Closed -$5.98M
INSM icon
78
Insmed
INSM
$28.7B
– –
-1,075,000
Closed -$82M
ITOS
79
DELISTED
iTeos Therapeutics
ITOS
– –
-900,000
Closed -$5.37M
KNSA icon
80
Kiniksa Pharmaceuticals
KNSA
$5.97B
– –
-169,864
Closed -$3.77M
LQDA icon
81
Liquidia Corp
LQDA
$7.95B
– –
-1,227,403
Closed -$18.1M
RARE icon
82
Ultragenyx Pharmaceutical
RARE
$2.54B
– –
-500,000
Closed -$18.1M
SRPT icon
83
Sarepta Therapeutics
SRPT
$1.77B
– –
-200,000
Closed -$12.8M
URGN icon
84
UroGen Pharma
URGN
$2.22B
– –
-2,152,957
Closed -$23.8M
VRNA
85
DELISTED
Verona Pharma
VRNA
– –
-267,627
Closed -$17M
1 2 3
4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Vestal Point Capital held 85 positions worth $1.9B, up 36% from $1.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Vestal Point Capital deployed $505M of net new capital in Q2 2025, opening 22 new positions and adding to 26 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 1,200,000 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was uniQure, an estimated $14.7M trimmed.

  • Vestal Point Capital's largest Q2 2025 buy was Jazz Pharmaceuticals: 1,200,000 shares worth $127M.
  • Vestal Point Capital added most to Amicus Therapeutics in Q2 2025, an estimated $49.2M increase.
  • Vestal Point Capital's biggest Q2 2025 reduction was uniQure, cutting an estimated $14.7M.
  • Vestal Point Capital fully exited Insmed in Q2 2025, selling an estimated $82M.
  • Vestal Point Capital's ten largest holdings make up 45% of its $1.9B portfolio in Q2 2025.
  • Vestal Point Capital opened 22 new positions and closed 13 in Q2 2025.
  • Vestal Point Capital's portfolio value rose 36% quarter-over-quarter to $1.9B.

Based on Vestal Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.